Drawing for GASTROBIOME

USPTO serial 97690923

GASTROBIOME

Reviewed by CopyMark Law Group

Reg. 7349101Status 700Registered
Filing date
Status date
Registration date
Apr 2, 2024
Examiner
HOWELL, MATTHEW P
Law office
TMO LAW OFFICE 123

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with GASTROBIOME?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

ANDREW D. SKALE

ANDREW D. SKALE MINTZ, LEVIN, COHN, FERRIS, GLOVSKY AND POPEO, P.C3580 CARMEL MOUNTAIN ROADSUITE 300SAN DIEGO, CA 92130

Goods and services

ClassDescriptionStatusFirst use
042Research and development of pharmaceuticals, neutriceuticals, and medicines; Pharmaceutical research and development; Research and development of technology in the field of intestinal and cardiovascular pharmaceuticals, therapeutics, and neutriceuticals; Medical research and product development services in the field of intestinal and cardiovascular drug development, therapeutics, and neutriceuticals; Drug discovery services; Pharmaceutical drug development services; Pharmaceutical product evaluation; Pharmaceutical products development; Research and development in the intestinal and cardiovascular pharmaceutical and biotechnology fields; Biochemical research and development; Biological research; Biomedical research services; Conducting early evaluations in the field of new pharmaceuticals; Laboratory research services relating to intestinal and cardiovascular pharmaceuticals; Product research and development; Providing medical and scientific research information in the field of pharmaceuticals, neutriceuticals, and medicinesACTIVEFeb 27, 2024

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Apr 2, 2024NRCSNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Apr 2, 2024R.SRREGISTERED-SUPPLEMENTAL REGISTERYour mark is registered on the Supplemental Register, which is available for marks that are not yet distinctive enough for the Principal Register but can still identify a source. Protection is more limited than Principal Register registration but can later support a Principal Register application.
Mar 4, 2024EXPTEXPARTE APPEAL TERMINATED—
Mar 1, 2024AAUANOTICE OF ACCEPTANCE OF AMENDMENT TO ALLEGE USE E-MAILED—
Feb 29, 2024CNTAAPPROVED FOR REGISTRATION SUPPLEMENTAL REGISTER—
Feb 29, 2024IUAAUSE AMENDMENT ACCEPTED—
Feb 29, 2024EXPIEX PARTE APPEAL-INSTITUTED—
Feb 29, 2024JURTJURISDICTION RESTORED TO EXAMINING ATTORNEY—
Feb 29, 2024EXAFEXPARTE APPEAL RECEIVED AT TTAB—
Feb 28, 2024AUPCAMENDMENT TO USE PROCESSING COMPLETE—
Feb 28, 2024IUAFUSE AMENDMENT FILED—
Feb 28, 2024EAAUTEAS AMENDMENT OF USE RECEIVED—
Feb 28, 2024ERFRTEAS REQUEST FOR RECONSIDERATION RECEIVED—
Nov 21, 2023XELGAPPLICATION EXTENSION GRANTED/RECEIPT PROVIDED—
Nov 21, 2023XELRAPPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED—
Aug 29, 2023GNFNNOTIFICATION OF FINAL REFUSAL EMAILED—
Aug 29, 2023GNFRFINAL REFUSAL E-MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Aug 29, 2023CNFRFINAL REFUSAL WRITTENA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Jul 26, 2023TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jul 26, 2023CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jul 26, 2023TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Apr 24, 2023XELGAPPLICATION EXTENSION GRANTED/RECEIPT PROVIDED—
Apr 24, 2023XELRAPPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED—
Jan 26, 2023GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jan 26, 2023GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jan 26, 2023CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jan 26, 2023DOCKASSIGNED TO EXAMINER—
Dec 17, 2022NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Nov 26, 2022NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance